عرض بسيط للتسجيلة

المؤلفBasha, Ahmad
المؤلفIbrahim, Mohamed Izham Mohamed
المؤلفHamad, Anas
المؤلفChandra, Prem
المؤلفOmar, Nabil E.
المؤلفAbdullah, Mohamed Abdul Jaber
المؤلفAldapt, Mahmood B.
المؤلفHussein, Radwa M.
المؤلفMahfouz, Ahmed
المؤلفAdel, Ahmad A.
المؤلفShwaylia, Hawraa M.
المؤلفEkeibed, Yaslem
المؤلفAbuMousa, Rami
المؤلفYassin, Mohamed A.
تاريخ الإتاحة2023-09-20T08:47:10Z
تاريخ النشر2021
اسم المنشورPLoS ONE
المصدرScopus
الرقم المعياري الدولي للكتاب19326203
معرّف المصادر الموحدhttp://dx.doi.org/10.1371/journal.pone.0255104
معرّف المصادر الموحدhttp://hdl.handle.net/10576/47789
الملخصBackground Iron deficiency anaemia (IDA) is a major health issues and common type of nutritional deficiency worldwide. For IDA treatment, intravenous (IV) iron is a useful therapy. Objective To determine the efficacy and cost-effectiveness (CE) of intravenous (IV) Ferric Carboxymaltose (FCM) versus IV Iron Sucrose (IS) in treating IDA. Data sources Electronic medical record i.e. Cerner system. Target population Adults patients with iron deficiency anaemia. Time horizon A 12-month period (01/01/2018-31/12/2018). Perspective Hamad Medical Corporation (HMC, a public hospital). Intervention IV Ferric Carboxymaltose versus IV Iron Sucrose. Outcome measures With regard to responses to treatment i.e., efficacy of treatment with FCM & IS in IDA patients, hemoglobin (Hgb), ferritin, and transferrin saturation (TSAT) levels were the primary outcomes. Additionally, the researchers also collected levels of iron, platelet, white blood cell (WBC), red blood cell (RBC), mean corpuscular hemoglobin (MCH), and mean corpuscular volume (MCV). The costs i.e. resources consumed (obtained from NCCCR-HMC) and the CE of FCM versus IS were the secondary outcomes. Results of base-case analysis There was a significant improvement in Hgb, RBC and MCH levels in the IS group than the FCM group. The overall cost of IS therapy was significantly higher than FCM. The medication cost for FCM was approximately 6.5 times higher than IS, nonetheless, it is cheaper in terms of bed cost and nursing cost. The cost effectiveness (CE) ratio illustrated that FCM and IS were significantly different in terms of Hgb, ferritin and MCH levels. Further, Incremental Cost Effectiveness Ratio (ICER) indicated that further justifications and decisions need to be made for FCM when using Hgb, iron, TSAT, MCH and MCV levels as surrogate outcomes. Results of sensitivity analysis Not applicable. Limitations The study did not consider the clinical or humanistic outcome. Conclusions The higher cost of FCM versus IS can be offset by savings in healthcare personnel time and bed space. ICER indicated that further justifications and decisions need to be made for FCM when using Hgb, iron, TSAT, MCH and MCV levels as surrogate outcomes.
اللغةen
الناشرPublic Library of Science
الموضوعferric carboxymaltose
ferritin
hemoglobin
iron
iron saccharate
transferrin
ferric carboxymaltose
ferric ion
iron saccharate
maltose
العنوانEfficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia
النوعArticle
رقم العدد8-Aug
رقم المجلد16
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة